FGTI-2734

产品说明书

Print
Chemical Structure| 1247018-19-4 同义名 : -
CAS号 : 1247018-19-4
货号 : A1177187
分子式 : C26H31FN6O2S
纯度 : 98+%
分子量 : 510.63
MDL号 : MFCD32174296
存储条件:

Pure form Inert atmosphere, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 : -
动物实验配方:
生物活性
描述 Mutations in KRAS drive a series of oncogenic events, including tumor cell proliferation and invasion, resistance to apoptosis, and sustained angiogenesis. Farnesyltransferase (FT) and geranylgeranyltransferase-1 (GGT-1) are two enzymes involved in KRAS prenylation. FGTI-2734 is a potent RAS C-terminal mimetic dual FT and GGT-1 inhibitor with IC50 values of 250 and 520 nM, respectively. FTI-2148 inhibited the prenylation of HDJ2, RAP1A, KRAS, and NRAS in NRAS-transformed NIH3T3 cells as compared with DMSO-treated controls. In human pancreatic (MiaPaCa2) and lung (H460) cancer cells, FGTI-2734 at 3 - 30 µM increased the cytosolic accumulation of HRAS and RAP1A, and inhibited the membrane association of KRAS and NRAS. Treatment with FGTI-2734 at 30 µM prevented GFP-KRASG12V-CVIM localization to the membrane in human cancer cell lines including MiaPaCa2, H460, Calu6, A549, and DLD1 cells. In MiaPaCa2 cells, administration with FGTI-2734 at 30 μM inhibited the RAF-1 kinase activity. FGTI-2734 treatment at the doses of 1 - 30 µM suppressed HDJ2 farnesylation and RAP1A geranylgeranylation in MiaPaCa2, L3.6pl, Calu6, A549, H460, and DLD1 cells, and induced Caspase-3 and PARP cleavage only in MiaPaCa2, L3.6pl, and Calu6 cells lines. In mouse xenograft models, intraperitoneal administration of FGTI-2734 (100 mg/kg/day) inhibited the growth of KRAS-dependent MiaPaCa2 tumors but not the mutant KRAS-independent tumors[1].
作用机制 FGTI-2734 is a potent CAAX tetrapeptide mimetic dual inhibitor of FT and GGT-1 that inhibits the membrane localization of KRAS in multiple human cancer cell lines.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.79mL

1.96mL

0.98mL

19.58mL

3.92mL

1.96mL

参考文献

[1]Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, Kang Y, Kim MP, Delitto A, Underwood PW, Fleming JB, Trevino JG, Hamilton AD, Sebti SM. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. Clin Cancer Res. 2019 Oct 1;25(19):5984-5996. doi: 10.1158/1078-0432.CCR-18-3399. Epub 2019 Jun 21. PMID: 31227505; PMCID: PMC6774803.